Semnurpharma - Getting back to normal

Getting back to normal

About
Partners
Chronic Back Pain
Science
Investors
Join Our Team
Contact Us

Our Team

Executive Chairman

Jaisim Shah

Chief Financial Officer & Senior Vice President

Stephen Ma

Executive Director of Administrative Operations and Head of Human Resources

Gigi DeGuzman

Chief Technical Officer & Senior Vice President

Suketu D. Desai, PhD

Chief Medical Officer & Senior Vice President

Dmitri Lissin, M.D.

Overview
Partners
Our Culture
Product
Publications
Join Our Team
Presentation
Contact Us

Connect, follow and have a conversation with us

960 San Antonio Road, Palo Alto, CA, 94303
(650) 516-4310
info@semnurpharma.com

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces on November 6th, 2024 the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali.

Check Our Press Release

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

Reference:
@srinipillay 2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered, according to a proprietary study by Syneos Health. *